Breast cancer drug 30% better than tamoxifen
You can read about the results of these findings in the New England Journal of Medicine.
Dr. Paul Goss, an eminent cancer researcher said 'I believe this trial will change the practice of breast cancer for women worldwide. This trial, I think, will put....perhaps not overnight....but will put an end to tamoxifen being the treatment of choice in hormone-dependent breast cancer for five years after diagnosis. The result is an astounding improvement in efficacy, a substantial and clinically important reduction in recurrence. To give you a sense of it, it outstrips any chemotherapy advantage that we've seen for breast cancer patients in the past. So this is an important step that excels and exceeds the benefits from all types of adjuvant chemotherapy that have been used in this disease.'
This trial was led by Dr. R Coombes, Imperial College of Medicine, London, UK. Pfizer funded the trial, Pfizer also produces Exemestane (Aromasin).
All the 4,700 were post menopausal. They had got breast cancer as a result of estrogen boosts.
These trials are not relevant to pre-menopausal women. It is only relevant to women whose tumors (tumours) were estrogen fuelled.
The trial found that:
-- Women on exemestane had fewer side effects than those on tamoxifen.
-- Women on exemestane had 56% lower risk of getting cancer on the other breast than those on tamoxifen.
-- Women on exemastane were 50% less likely to get cancer elsewhere in the body than those on tamoxifen.
Tamoxifen is generally given to women after they have breast cancer (and the treatment such as surgery, radiation, chemotherapy or all three). Tamoxifen inhibits estrogen, estrogen fuels most breast cancer tumors (tumours).
After five years on tamoxifen, tumors seem to become resistant to it and its effect goes down.
View drug information on Aromasin Tablets.
Cancer de sân de droguri 30% mai bine decât tamoxifen - Breast cancer drug 30% better than tamoxifen - articole medicale engleza - startsanatate